US 12,070,442 B2
Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
Kamran Hosseini, Pleasanton, CA (US); Dennis Elias Saadeh, Irvine, CA (US); and Richard L. Lindstrom, Pleasanton, CA (US)
Assigned to SURFACE OPHTHALMICS, INC., Pleasanton, CA (US)
Appl. No. 17/418,813
Filed by SURFACE OPHTHALMICS, INC., Pleasanton, CA (US)
PCT Filed Dec. 4, 2019, PCT No. PCT/US2019/064371
§ 371(c)(1), (2) Date Jun. 26, 2021,
PCT Pub. No. WO2020/139525, PCT Pub. Date Jul. 2, 2020.
Claims priority of provisional application 62/785,312, filed on Dec. 27, 2018.
Prior Publication US 2022/0071945 A1, Mar. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/343 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01)
CPC A61K 31/343 (2013.01) [A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61K 9/08 (2013.01)] 23 Claims
 
1. A pharmaceutical composition comprising:
(a) a first component comprising a combination of (i) mycophenolic acid or a pharmaceutically acceptable salt thereof at a concentration of 0.05% w/w to 1.0% w/w, and (ii) betamethasone or a pharmaceutically acceptable salt thereof at a concentration of about 0.005% w/w to 0.05% w/w; and
(b) a pharmaceutically acceptable carrier.